




Belgian Cancer Registry

CANCER FACT SHEET 2024

KIDNEY CANCER

ICD-10 C64



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Kidney cancer incidence: by region	5
1.1.1. Kidney cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024.....	5
1.2. Kidney cancer incidence: by tumour stage	7
1.2.1. Kidney cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	7
1.2.2. Kidney cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	7
1.2.3. Kidney cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024.....	8
2. CANCER INCIDENCE TRENDS	9
2.1. Kidney cancer incidence trends: by region.....	9
2.1.1. Kidney cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	9
2.1.2. Kidney cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	10
2.2. Kidney cancer incidence trends: by tumour stage.....	11
2.2.1. Kidney cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards	11
2.3. Kidney cancer incidence trends: by age group.....	13
2.3.1. Kidney cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	13
2.3.2. Kidney cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024.....	14
3. CANCER PREVALENCE	15
3.1. Kidney cancer prevalence: by region.....	15
3.1.1. Kidney cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024.....	15
4. CANCER SURVIVAL.....	16
4.1. Kidney cancer survival: by region	16
4.1.1. Kidney cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024	16
4.2. Kidney cancer survival: by tumour stage	18
4.2.1. Kidney cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024.....	18
4.2.2. Kidney cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024	19
4.2.3. Kidney cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024.....	20
5. CANCER SURVIVAL TRENDS.....	21
5.1. Kidney cancer survival trends: by tumour stage.....	21

5.1.1. Kidney cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024	21
6. CANCER MORTALITY	23
6.1. Kidney cancer mortality: by region	23
6.1.1. Kidney cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023	23
7. CANCER MORTALITY TRENDS.....	25
7.1. Kidney cancer mortality trends: by region	25
7.1.1. Kidney cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023	25
7.1.2. Kidney cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023	27

1. CANCER INCIDENCE



1.1. Kidney cancer incidence: by region

1.1.1. Kidney cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	3	3	0	0	2	3	5	25	33	70	85	146	200	251	243	208	142	66	25	1	1,511	27.0
	[1.0]	[0.9]	[0.0]	[0.0]	[0.6]	[0.8]	[1.3]	[6.6]	[8.6]	[18.8]	[21.6]	[36.6]	[52.6]	[77.3]	[90.5]	[97.7]	[112.2]	[80.3]	[76.7]	[15.7]	[26.1]	(25.7; 28.4)
Brussels	0	1	0	0	1	0	0	2	0	4	4	8	13	11	15	9	11	5	1	0	85	21.1
	[0.0]	[2.5]	[0.0]	[0.0]	[2.4]	[0.0]	[0.0]	[4.2]	[0.0]	[9.1]	[9.7]	[22.1]	[44.0]	[50.6]	[88.3]	[69.9]	[133.7]	[98.7]	[44.5]	[0.0]	[13.9]	(16.5; 25.8)
Flanders	3	1	0	0	1	1	3	14	23	46	53	93	132	152	149	153	101	43	20	1	989	28.7
	[1.8]	[0.5]	[0.0]	[0.0]	[0.5]	[0.5]	[1.4]	[6.5]	[10.3]	[21.6]	[23.5]	[38.9]	[56.8]	[75.7]	[89.7]	[113.3]	[120.6]	[77.3]	[91.4]	[23.8]	[29.3]	(26.9; 30.5)
Wallonia	0	1	0	0	0	2	2	9	10	20	28	45	55	88	79	46	30	18	4	0	437	25.3
	[0.0]	[1.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.7]	[7.6]	[8.5]	[17.2]	[22.3]	[36.4]	[46.6]	[86.0]	[92.4]	[70.7]	[86.8]	[83.9]	[47.2]	[0.0]	[24.2]	(22.9; 27.7)
Females																						
Belgium	4	2	0	0	0	3	5	14	18	19	49	70	82	93	108	131	93	53	17	2	763	12.0
	[1.4]	[0.6]	[0.0]	[0.0]	[0.0]	[0.8]	[1.3]	[3.6]	[4.7]	[5.1]	[12.7]	[17.8]	[21.2]	[27.0]	[36.2]	[51.2]	[53.5]	[39.1]	[23.6]	[9.3]	[12.8]	(11.1; 12.8)
Brussels	0	0	0	0	0	1	1	2	0	0	6	2	4	6	7	4	4	2	1	0	40	7.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.8]	[4.1]	[0.0]	[0.0]	[15.6]	[5.8]	[13.1]	[23.9]	[32.5]	[21.6]	[31.2]	[20.7]	[17.7]	[0.0]	[6.3]	(5.4; 10.2)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	3	1	0	0	0	0	4	8	10	10	19	47	45	54	62	87	65	38	13	0	466	12.0
	[1.9]	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[3.7]	[4.5]	[4.7]	[8.6]	[20.2]	[19.4]	[26.1]	[35.0]	[56.2]	[59.3]	[43.8]	[28.7]	[0.0]	[13.5]	(10.9; 13.1)
Wallonia	1	1	0	0	0	2	0	4	8	9	24	21	33	33	39	40	24	13	3	2	257	12.8
	[1.1]	[1.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[3.3]	[6.8]	[7.7]	[19.1]	[16.8]	[26.7]	[29.2]	[39.1]	[48.3]	[46.6]	[33.2]	[14.2]	[30.1]	[13.6]	(11.3; 14.4)

1.2. Kidney cancer incidence: by tumour stage

1.2.1. Kidney cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	234 [6.9]	441 [45.3]	247 [53.6]	922 [15.9]	16.4 (15.3; 17.5)	117 [3.5]	187 [18.2]	182 [27.6]	486 [8.1]	7.6 (7.0; 8.3)
II	43 [1.3]	56 [5.8]	49 [10.6]	148 [2.6]	2.7 (2.3; 3.1)	17 [0.5]	19 [1.8]	33 [5.0]	69 [1.2]	1.1 (0.8; 1.3)
III	24 [0.7]	55 [5.7]	40 [8.7]	119 [2.1]	2.1 (1.7; 2.5)	12 [0.4]	19 [1.8]	28 [4.2]	59 [1.0]	0.9 (0.7; 1.1)
IV	35 [1.0]	87 [8.9]	82 [17.8]	204 [3.5]	3.7 (3.2; 4.2)	16 [0.5]	26 [2.5]	43 [6.5]	85 [1.4]	1.3 (1.0; 1.6)
X/NA	33 [1.0]	55 [5.7]	24 [5.2]	118 [2.0]	2.1 (1.7; 2.5)	16 [0.5]	32 [3.1]	10 [1.5]	64 [1.1]	1.0 (0.8; 1.3)

1.2.2. Kidney cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	225 [6.6]	393 [40.4]	121 [26.3]	739 [12.7]	13.0 (12.0; 13.9)	103 [3.1]	171 [16.6]	85 [12.9]	359 [6.0]	5.8 (5.2; 6.4)
II	40 [1.2]	40 [4.1]	30 [6.5]	110 [1.9]	2.0 (1.6; 2.3)	13 [0.4]	18 [1.7]	11 [1.7]	42 [0.7]	0.7 (0.5; 0.9)
III	38 [1.1]	97 [10.0]	51 [11.1]	186 [3.2]	3.3 (2.8; 3.8)	24 [0.7]	27 [2.6]	47 [7.1]	98 [1.6]	1.5 (1.2; 1.8)
IV	18 [0.5]	36 [3.7]	27 [5.9]	81 [1.4]	1.4 (1.1; 1.8)	11 [0.3]	11 [1.1]	11 [1.7]	33 [0.6]	0.5 (0.4; 0.7)
X/NA	48 [1.4]	128 [13.1]	213 [46.2]	395 [6.8]	7.3 (6.6; 8.0)	27 [0.8]	56 [5.4]	142 [21.5]	231 [3.9]	3.4 (3.0; 3.9)

1.2.3. Kidney cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	251 [7.4]	467 [48.0]	245 [53.2]	963 [16.6]	17.1 (16.0; 18.2)	121 [3.6]	207 [20.1]	180 [27.3]	508 [8.5]	8.0 (7.3; 8.7)
II	40 [1.2]	40 [4.1]	45 [9.8]	125 [2.2]	2.3 (1.9; 2.7)	13 [0.4]	18 [1.7]	16 [2.4]	47 [0.8]	0.7 (0.5; 1.0)
III	35 [1.0]	94 [9.7]	60 [13.0]	189 [3.3]	3.4 (2.9; 3.9)	22 [0.7]	28 [2.7]	54 [8.2]	104 [1.7]	1.6 (1.3; 1.9)
IV	37 [1.1]	87 [8.9]	83 [18.0]	207 [3.6]	3.7 (3.2; 4.3)	19 [0.6]	26 [2.5]	45 [6.8]	90 [1.5]	1.4 (1.1; 1.7)
X/NA	6 [0.2]	6 [0.6]	9 [2.0]	27 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	4 [0.4]	1 [0.2]	14 [0.2]	0.2 (0.1; 0.4)

2. CANCER INCIDENCE TRENDS



2.1. Kidney cancer incidence trends: by region

2.1.1. Kidney cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	N	816	845	859	894	953	964	995	1,007	1,051	1,071	1,080	1,150	1,191	1,142	1,172	1,308	1,280	1,303	1,374	1,523	1,511		
	CR	16.0	16.5	16.7	17.3	18.2	18.3	18.7	18.8	19.4	19.7	19.7	20.9	21.5	20.5	20.9	23.2	22.6	23.0	24.1	26.4	26.1		
	ESR2013	19.1	19.6	19.7	20.2	21.3	21.3	21.9	21.2	22.1	22.2	22.2	23.2	23.7	22.6	22.8	25.1	24.2	24.3	25.2	27.6	27.0	1.8 (1.5; 2.0)	2004-2024
																							1.4 (1.2; 1.7)	2004-2022
																							4.7 (1.7; 7.7)	2023-2024
Brussels	N	58	69	42	56	76	61	74	69	83	84	66	85	79	64	91	93	78	84	91	73	85		
	CR	12.1	14.3	8.6	11.3	15.0	11.8	14.0	12.7	15.0	15.0	11.6	14.8	13.6	11.0	15.5	15.7	13.0	14.0	15.2	12.0	13.9		
	ESR2013	16.5	20.2	11.9	16.0	22.2	16.6	19.6	17.6	22.6	22.4	17.5	21.3	19.9	16.5	23.3	22.7	19.6	20.3	22.5	17.9	21.1	1.2 (0.1; 2.4)	2004-2024
Flanders	N	501	522	540	570	584	601	656	650	662	669	715	714	740	744	741	817	850	796	901	1,005	989		
	CR	16.9	17.5	18.0	18.9	19.2	19.6	21.3	20.9	21.1	21.2	22.6	22.4	23.1	23.1	22.9	25.1	25.9	24.2	27.2	30.0	29.3		
	ESR2013	19.6	19.9	20.5	21.0	21.3	22.0	23.9	22.4	22.8	22.8	24.0	23.7	24.0	23.9	23.3	25.4	26.2	24.1	26.8	29.4	28.7	1.7 (1.3; 2.0)	2004-2024
Wallonia	N	257	254	277	268	293	302	265	288	306	318	299	351	372	334	340	398	352	423	382	445	437		
	CR	15.7	15.4	16.7	16.1	17.5	17.9	15.6	16.8	17.7	18.3	17.2	20.1	21.2	18.9	19.2	22.4	19.8	23.7	21.3	24.7	24.2		
	ESR2013	18.8	18.7	20.2	19.6	21.0	21.1	18.5	19.7	20.1	21.0	19.5	22.5	24.1	21.3	21.4	24.8	21.2	25.3	22.6	26.1	25.3	1.4 (0.9; 1.9)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Kidney cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	N	526	536	534	521	547	528	560	658	602	617	616	593	639	652	642	687	652	662	701	714	763	0.7 (0.4; 1.0)	2004-2024
	CR	9.9	10.0	9.9	9.6	10.1	9.6	10.1	11.8	10.7	10.9	10.9	10.4	11.2	11.3	11.1	11.8	11.2	11.3	11.9	12.0	12.8		
	ESR2013	10.2	10.2	10.1	9.7	10.1	9.7	10.2	11.6	10.6	10.8	10.7	10.3	10.8	11.0	10.8	11.3	10.6	10.7	11.3	11.3	12.0		
Brussels	N	28	33	35	27	34	36	38	45	40	49	41	42	41	30	37	41	48	41	47	43	40	1.3 (0.2; 2.4)	2004-2024
	CR	5.4	6.3	6.6	5.1	6.3	6.5	6.8	7.8	6.8	8.3	6.9	7.0	6.7	4.9	6.0	6.7	7.7	6.6	7.6	6.8	6.3		
	ESR2013	6.0	7.1	7.6	5.9	7.2	7.4	7.8	8.9	8.3	10.2	8.6	8.8	8.2	6.2	7.7	8.3	9.1	7.7	9.1	8.3	7.8		
Flanders	N	350	337	336	347	352	343	373	413	388	384	404	372	417	415	432	464	422	418	433	480	466	0.4 (0.1; 0.8)	2004-2024
	CR	11.5	11.0	10.9	11.2	11.3	10.9	11.8	12.9	12.1	11.9	12.4	11.4	12.7	12.6	13.0	13.9	12.6	12.4	12.8	14.0	13.5		
	ESR2013	11.6	10.9	10.8	11.0	10.9	10.6	11.4	12.3	11.3	11.1	11.6	10.7	11.7	11.7	12.0	12.6	11.3	11.2	11.5	12.6	12.0		
Wallonia	N	148	166	163	147	161	149	149	200	174	184	171	179	181	207	173	182	182	203	221	191	257	1.0 (0.3; 1.6)	2004-2024
	CR	8.5	9.5	9.3	8.3	9.1	8.3	8.3	11.0	9.6	10.1	9.3	9.7	9.8	11.2	9.3	9.8	9.8	10.9	11.8	10.2	13.6		
	ESR2013	8.8	9.8	9.3	8.4	9.4	8.4	8.6	11.0	9.8	10.2	9.5	9.8	9.8	11.1	9.2	9.5	9.4	10.5	11.3	9.6	12.8		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Kidney cancer incidence trends: by tumour stage

2.2.1. Kidney cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	755	766	844	988	963			380	386	425	458	508		
	CR	13.3	13.5	14.8	17.1	16.6			6.5	6.6	7.2	7.7	8.5		
	ESR2013	14.2	14.2	15.4	17.8	17.1	4.6 (4.2; 4.9)	2004-2024	6.2	6.3	6.9	7.3	8.0	3.3 (2.8; 3.9)	2004-2024
							6.8 (5.4; 8.2)	2004-2010						6.9 (4.8; 9.0)	2004-2010
							3.6 (3.1; 4.2)	2011-2024						0.6 (-1.8; 3.0)	2011-2014
														2.4 (1.4; 3.4)	2015-2024
II	N	105	110	113	103	125			53	62	60	53	47		
	CR	1.9	1.9	2.0	1.8	2.2			0.9	1.1	1.0	0.9	0.8		
	ESR2013	2.0	2.1	2.1	1.9	2.3	-0.1 (-1.1; 0.9)	2004-2024	0.9	1.0	1.0	0.8	0.7	-0.3 (-1.5; 1.0)	2004-2024
III	N	180	194	178	210	189			95	94	94	104	104		
	CR	3.2	3.4	3.1	3.6	3.3			1.6	1.6	1.6	1.8	1.7		
	ESR2013	3.4	3.6	3.3	3.8	3.4	1.4 (0.7; 2.1)	2004-2024	1.5	1.5	1.5	1.6	1.6	1.1 (0.5; 1.7)	2004-2024
							8.2 (3.8; 12.8)	2004-2008							
							-1.5 (-4.6; 1.7)	2009-2012							
							0.2 (-0.8; 1.3)	2013-2024							
IV	N	187	180	200	191	207			88	89	100	79	90		
	CR	3.3	3.2	3.5	3.3	3.6			1.5	1.5	1.7	1.3	1.5		
	ESR2013	3.6	3.4	3.7	3.5	3.7	0.7 (0.1; 1.3)	2004-2024	1.4	1.4	1.6	1.2	1.4	-0.3 (-1.2; 0.5)	2004-2024
X/NA	N	53	53	39	31	27			36	31	22	20	14		
	CR	0.9	0.9	0.7	0.5	0.5			0.6	0.5	0.4	0.3	0.2		

Stage	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
ESR2013	1.0	1.0	0.7	0.6	0.5	-10.6 (-11.6; -9.6)	2004-2024	0.6	0.5	0.4	0.3	0.2	-9.3 (-10.5; -8.1)	2004-2024
						-8.8 (-9.6; -7.9)	2004-2022							
						-25.3 (-33.5; -16.0)	2023-2024							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Kidney cancer incidence trends: by age group

2.3.1. Kidney cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59 N	274	243	271	284	302	289	287	313	323	338	319	343	333	313	296	347	312	357	316	392	369	0.9 (0.4; 1.4)	2004-2024
CR	8.6	7.6	8.4	8.8	9.3	8.8	8.7	9.5	9.7	10.2	9.6	10.3	10.0	9.4	8.9	10.4	9.3	10.7	9.4	11.6	10.9		
ESR2013	9.1	7.9	8.7	9.1	9.6	9.1	8.9	9.6	9.8	10.2	9.6	10.2	9.9	9.2	8.7	10.2	9.2	10.5	9.3	11.6	11.0		
60-74 N	361	385	393	384	426	429	436	439	454	445	466	517	548	513	545	581	611	589	660	689	694	1.3 (1.0; 1.6)	2004-2024
CR	53.0	56.2	57.2	54.9	59.8	59.0	58.8	58.1	59.0	56.8	58.5	63.6	65.8	59.9	62.0	64.7	66.6	63.0	69.8	71.8	71.3		
ESR2013	52.8	56.0	57.2	55.6	60.7	59.9	59.6	58.8	60.2	57.3	60.0	65.0	67.4	61.1	62.8	65.6	67.4	63.8	70.8	72.7	72.3		
75+ N	168	205	187	220	223	237	266	242	269	280	283	286	297	311	324	370	346	350	392	435	442	2.6 (2.2; 3.0)	2004-2024
CR	57.3	67.7	59.5	67.5	66.2	68.6	75.1	67.0	72.9	74.5	73.8	73.1	75.2	78.8	81.6	91.6	83.7	84.1	90.9	97.7	96.0		
ESR2013	53.8	61.0	56.1	62.1	63.1	66.6	74.8	63.4	70.0	74.1	72.2	71.8	73.2	77.8	80.0	90.1	83.9	83.5	89.5	96.4	95.1		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Kidney cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59 N	144	146	129	129	140	138	131	179	163	154	148	149	141	134	152	134	146	157	157	167	178		
CR	4.6	4.6	4.1	4.0	4.4	4.3	4.0	5.5	5.0	4.7	4.5	4.5	4.3	4.1	4.6	4.1	4.4	4.8	4.8	5.0	5.3		
ESR2013	4.8	4.8	4.2	4.1	4.5	4.3	4.1	5.5	5.0	4.7	4.5	4.5	4.3	4.0	4.6	4.0	4.4	4.7	4.7	5.0	5.3	0.9 (-0.1; 1.9)	2004-2024
																						0.1 (-0.6; 0.8)	2004-2023
																						17.4 (-3.3; 42.4)	2024-2024
60-74 N	218	217	221	210	215	212	219	233	217	239	229	231	252	292	253	278	255	241	269	272	283		
CR	28.1	28.0	28.6	26.9	27.3	26.5	27.0	28.3	26.0	28.2	26.7	26.5	28.2	31.8	26.9	29.0	26.1	24.2	26.8	26.7	27.5		
ESR2013	27.6	27.5	28.2	26.8	27.3	26.7	27.3	28.3	26.4	28.5	27.1	26.9	28.9	32.2	27.1	29.1	26.3	24.4	26.8	26.8	27.7	-0.1 (-0.5; 0.3)	2004-2024
75+ N	157	164	174	173	185	171	204	236	216	220	231	205	236	216	231	267	240	259	265	267	296		
CR	30.2	30.9	32.0	31.0	32.5	29.6	34.8	39.8	36.0	36.4	37.9	33.2	38.3	35.3	37.8	43.5	38.7	41.8	41.8	41.4	44.9		
ESR2013	30.2	30.0	31.1	30.6	31.8	28.8	35.1	39.3	35.8	36.2	38.4	34.1	37.4	35.7	39.2	44.7	38.7	42.4	43.6	42.4	46.4	2.1 (1.6; 2.6)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Kidney cancer prevalence: by region

3.1.1. *Kidney cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024*

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	1,401	5,497	8,787	10,823	12,067	707	2,781	4,672	5,984	6,801
	CR	24.0	94.3	150.7	186	207	11.8	46.4	77.9	100	113
	ESR2013	24.7	96.8	155.1	191.4	214.0	10.9	43.0	71.6	91.2	103.0
Brussels	N	77	306	526	668	750	37	172	296	391	440
	CR	12.5	49.7	85.5	108.6	121.9	5.8	26.9	46.2	61.1	68.7
	ESR2013	18.8	73.1	127.3	163.3	185.0	7.2	32.6	56.4	73.9	82.9
Flanders	N	914	3,566	5,632	6,943	7,724	438	1,770	2,978	3,796	4,319
	CR	26.9	104.9	165.7	204.2	227.2	12.6	51.1	85.9	109.6	124.6
	ESR2013	26.1	101.5	160.4	197.7	220.2	11.1	45.0	75.1	95.1	107.6
Wallonia	N	410	1,625	2,629	3,212	3,593	232	839	1,398	1,797	2,042
	CR	22.6	89.5	144.9	177.0	198.0	12.3	44.4	74.0	95.1	108.0
	ESR2013	23.4	92.5	150.6	184.6	207.3	11.5	41.3	68.3	87.5	99.0

4. CANCER SURVIVAL



4.1. Kidney cancer survival: by region

4.1.1. Kidney cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All ages 15+	19,032	89.5% (89.0%; 90.0%)	82.7% (82.0%; 83.4%)	79.0% (78.1%; 80.0%)	72.2% (70.0%; 74.5%)
Males						
Belgium	All ages 15+	12,523	89.4% (88.8%; 90.0%)	82.4% (81.6%; 83.3%)	78.6% (77.5%; 79.8%)	72.1% (69.4%; 75.0%)
	15-59	3,285	94.3% (93.4%; 95.1%)	89.1% (87.9%; 90.3%)	86.8% (85.5%; 88.2%)	81.9% (79.7%; 84.1%)
	60-74	5,787	91.3% (90.5%; 92.1%)	84.2% (83.1%; 85.4%)	79.6% (78.2%; 81.1%)	71.5% (68.7%; 74.4%)
	75+	3,464	81.7% (80.1%; 83.3%)	73.2% (71.0%; 75.5%)	69.1% (65.9%; 72.4%)	63.9% (55.1%; 74.1%)
Brussels	All ages 15+	789	88.3% (85.8%; 90.9%)	81.7% (78.3%; 85.3%)	78.2% (74.0%; 82.7%)	69.5% (60.2%; 80.3%)
	15-59	265	90.6% (87.1%; 94.3%)	84.4% (79.9%; 89.2%)	81.9% (76.9%; 87.3%)	71.3% (62.7%; 81.1%)
	60-74	331	89.8% (86.3%; 93.5%)	83.3% (78.5%; 88.5%)	78.3% (72.2%; 84.8%)	73.7% (63.4%; 85.7%)
	75+	193	82.4% (76.1%; 89.3%)	75.2% (66.4%; 85.1%)	71.5% (60.0%; 85.2%)	57.7% (34.1%; 97.6%)
Flanders	All ages 15+	8,013	89.2% (88.4%; 90.0%)	82.1% (81.0%; 83.2%)	78.3% (76.9%; 79.8%)	72.8% (69.4%; 76.5%)
	15-59	1,949	94.8% (93.8%; 95.8%)	89.7% (88.3%; 91.2%)	87.0% (85.3%; 88.8%)	83.4% (80.9%; 86.0%)
	60-74	3,603	91.3% (90.3%; 92.3%)	84.1% (82.6%; 85.5%)	79.8% (78.1%; 81.6%)	70.3% (66.8%; 73.9%)
	75+	2,473	81.8% (80.0%; 83.6%)	73.3% (70.6%; 76.0%)	69.3% (65.7%; 73.0%)	68.3% (58.0%; 80.5%)
Wallonia	All ages 15+	3,723	90.1% (89.0%; 91.2%)	83.3% (81.7%; 84.9%)	79.3% (77.1%; 81.6%)	71.3% (66.6%; 76.3%)

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	1,072	94.2% (92.7%; 95.7%)	89.2% (87.1%; 91.2%)	87.7% (85.4%; 90.1%)	81.8% (77.8%; 86.0%)
	60-74	1,854	91.5% (90.1%; 93.0%)	84.6% (82.6%; 86.7%)	79.5% (76.9%; 82.2%)	73.0% (68.0%; 78.4%)
	75+	798	81.2% (77.9%; 84.6%)	72.4% (67.7%; 77.4%)	67.5% (60.2%; 75.8%)	51.5% (35.0%; 75.6%)
Females						
Belgium	All ages 15+	6,509	89.7% (88.9%; 90.6%)	83.2% (82.0%; 84.4%)	79.8% (78.3%; 81.4%)	72.4% (68.6%; 76.3%)
	15-59	1,489	95.5% (94.4%; 96.6%)	91.9% (90.4%; 93.4%)	89.0% (87.2%; 90.8%)	85.0% (82.2%; 87.9%)
	60-74	2,578	92.2% (91.1%; 93.3%)	84.7% (83.1%; 86.3%)	81.3% (79.4%; 83.2%)	74.5% (71.0%; 78.1%)
	75+	2,449	83.6% (81.9%; 85.3%)	76.4% (73.9%; 78.9%)	72.7% (69.3%; 76.3%)	62.0% (53.3%; 72.0%)
Brussels	All ages 15+	396	90.9% (87.8%; 94.2%)	84.0% (79.3%; 88.9%)	78.8% (72.9%; 85.3%)	72.2% (54.0%; 96.5%)
	15-59	121	91.9% (87.2%; 97.0%)	88.8% (83.1%; 94.9%)	85.5% (78.7%; 92.9%)	85.6% (78.0%; 93.9%)
	60-74	143	92.0% (87.3%; 96.8%)	85.3% (78.8%; 92.3%)	85.4% (78.2%; 93.2%)	88.3% (78.1%; 99.9%)
	75+	132	88.2% (81.7%; 95.3%)	78.0% (68.0%; 89.4%)	65.8% (52.9%; 81.7%)	21.7% (5.0%; 94.4%)
Flanders	All ages 15+	4,190	89.7% (88.7%; 90.8%)	83.2% (81.7%; 84.7%)	79.5% (77.5%; 81.5%)	71.3% (66.8%; 76.1%)
	15-59	866	96.2% (94.9%; 97.5%)	93.0% (91.2%; 94.8%)	90.1% (87.9%; 92.4%)	85.7% (82.3%; 89.3%)
	60-74	1,601	92.5% (91.2%; 93.9%)	84.8% (82.9%; 86.9%)	80.9% (78.6%; 83.4%)	75.0% (71.1%; 79.1%)
	75+	1,728	83.8% (81.8%; 85.9%)	76.8% (73.9%; 79.8%)	72.9% (68.8%; 77.2%)	60.2% (50.8%; 71.3%)
Wallonia	All ages 15+	1,923	89.4% (87.9%; 91.0%)	83.0% (80.9%; 85.2%)	80.8% (78.0%; 83.6%)	74.6% (68.2%; 81.6%)
	15-59	502	95.1% (93.2%; 97.1%)	90.6% (87.9%; 93.4%)	87.8% (84.6%; 91.2%)	83.8% (78.7%; 89.4%)
	60-74	834	91.6% (89.6%; 93.7%)	84.3% (81.5%; 87.3%)	81.2% (77.8%; 84.8%)	71.2% (64.5%; 78.6%)
	75+	589	81.5% (77.9%; 85.3%)	74.7% (69.7%; 80.1%)	73.9% (67.2%; 81.3%)	71.1% (54.0%; 93.6%)

4.2. Kidney cancer survival: by tumour stage

4.2.1. Kidney cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

cStage	Net Survival Probability, 2015-2024						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	19,032	89.5% (89.0%; 90.0%)	85.6% (85.0%; 86.2%)	82.7% (82.0%; 83.4%)	80.9% (80.1%; 81.7%)	79.0% (78.1%; 80.0%)	72.2% (70.0%; 74.5%)
Males							
All	12,523	89.4% (88.8%; 90.0%)	85.4% (84.6%; 86.2%)	82.4% (81.6%; 83.3%)	80.6% (79.6%; 81.6%)	78.6% (77.5%; 79.8%)	72.1% (69.4%; 75.0%)
I	6,095	97.5% (96.9%; 98.0%)	96.3% (95.5%; 97.1%)	94.5% (93.4%; 95.6%)	93.5% (92.2%; 94.8%)	92.4% (90.8%; 94.1%)	88.8% (83.8%; 94.1%)
II	1,117	96.3% (94.7%; 97.9%)	94.2% (92.1%; 96.3%)	91.8% (89.2%; 94.6%)	89.9% (86.7%; 93.2%)	85.8% (81.9%; 90.0%)	72.0% (63.2%; 82.1%)
III	901	85.8% (83.3%; 88.4%)	79.9% (76.8%; 83.0%)	76.1% (72.7%; 79.7%)	71.5% (67.6%; 75.6%)	68.1% (63.7%; 72.8%)	54.2% (43.6%; 67.2%)
IV	1,777	54.8% (52.4%; 57.2%)	40.2% (37.8%; 42.7%)	32.0% (29.6%; 34.5%)	26.5% (24.2%; 29.0%)	23.3% (20.9%; 25.9%)	8.7% (5.4%; 14.0%)
X/NA	2,736	92.4% (91.3%; 93.6%)	88.8% (87.3%; 90.3%)	86.8% (85.1%; 88.6%)	86.1% (84.2%; 88.1%)	84.2% (82.1%; 86.4%)	79.6% (75.3%; 84.1%)
Females							
All	6,509	89.7% (88.9%; 90.6%)	85.9% (84.9%; 86.9%)	83.2% (82.0%; 84.4%)	81.4% (80.1%; 82.8%)	79.8% (78.3%; 81.4%)	72.4% (68.6%; 76.3%)
I	3,187	98.6% (97.9%; 99.3%)	97.0% (96.0%; 98.1%)	95.5% (94.1%; 96.9%)	94.1% (92.3%; 95.8%)	93.6% (91.4%; 95.9%)	88.2% (81.1%; 96.0%)
II	597	92.3% (89.8%; 94.9%)	90.0% (86.9%; 93.2%)	87.2% (83.5%; 91.1%)	87.9% (83.7%; 92.4%)	83.3% (78.1%; 88.9%)	76.6% (63.4%; 92.6%)
III	501	84.9% (81.5%; 88.4%)	77.1% (72.9%; 81.5%)	74.6% (70.0%; 79.5%)	70.4% (65.2%; 76.0%)	68.6% (62.9%; 74.8%)	53.6% (42.3%; 68.0%)
IV	820	50.4% (47.0%; 54.1%)	35.8% (32.5%; 39.4%)	26.0% (22.9%; 29.5%)	22.6% (19.5%; 26.1%)	17.8% (14.9%; 21.4%)	12.4% (9.2%; 16.7%)
X/NA	1,443	92.9% (91.4%; 94.5%)	90.9% (89.0%; 92.8%)	89.7% (87.6%; 91.8%)	88.2% (85.8%; 90.7%)	87.2% (84.5%; 90.0%)	77.4% (71.7%; 83.7%)

4.2.2. Kidney cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	19,032	89.5% (89.0%; 90.0%)	85.6% (85.0%; 86.2%)	82.7% (82.0%; 83.4%)	80.9% (80.1%; 81.7%)	79.0% (78.1%; 80.0%)	72.2% (70.0%; 74.5%)
Males							
All	12,523	89.4% (88.8%; 90.0%)	85.4% (84.6%; 86.2%)	82.4% (81.6%; 83.3%)	80.6% (79.6%; 81.6%)	78.6% (77.5%; 79.8%)	72.1% (69.4%; 75.0%)
I	6,256	99.8% (99.4%; 100.2%)	99.5% (99.0%; 100.1%)	98.8% (98.0%; 99.6%)	98.9% (97.9%; 99.8%)	98.4% (97.3%; 99.6%)	96.9% (93.4%; 100.6%)
II	976	96.9% (95.5%; 98.4%)	95.3% (93.4%; 97.3%)	92.8% (90.3%; 95.3%)	92.2% (89.4%; 95.1%)	89.0% (85.6%; 92.6%)	77.6% (70.4%; 85.6%)
III	1,883	91.8% (90.3%; 93.2%)	86.6% (84.7%; 88.5%)	83.1% (80.8%; 85.3%)	79.4% (76.9%; 82.0%)	76.3% (73.4%; 79.3%)	65.0% (58.7%; 72.0%)
IV	667	59.4% (55.7%; 63.4%)	44.4% (40.6%; 48.6%)	37.4% (33.5%; 41.7%)	32.3% (28.4%; 36.7%)	28.6% (24.6%; 33.3%)	10.8% (6.3%; 18.6%)
X/NA	2,874	69.8% (68.0%; 71.7%)	60.4% (58.3%; 62.5%)	53.5% (51.2%; 56.0%)	48.6% (46.0%; 51.3%)	44.5% (41.5%; 47.8%)	33.4% (26.5%; 42.1%)
Females							
All	6,509	89.7% (88.9%; 90.6%)	85.9% (84.9%; 86.9%)	83.2% (82.0%; 84.4%)	81.4% (80.1%; 82.8%)	79.8% (78.3%; 81.4%)	72.4% (68.6%; 76.3%)
I	3,133	99.8% (99.4%; 100.3%)	99.8% (99.1%; 100.5%)	99.3% (98.3%; 100.3%)	98.6% (97.3%; 99.8%)	98.9% (97.4%; 100.3%)	92.5% (87.3%; 98.0%)
II	474	97.8% (96.0%; 99.6%)	96.1% (93.6%; 98.6%)	93.5% (90.2%; 96.8%)	93.7% (90.1%; 97.5%)	91.2% (86.8%; 95.9%)	91.0% (81.4%; 101.8%)
III	904	93.0% (91.1%; 95.0%)	88.0% (85.4%; 90.6%)	84.7% (81.7%; 87.7%)	81.2% (77.7%; 84.8%)	77.1% (73.1%; 81.3%)	63.1% (55.5%; 71.8%)
IV	281	59.9% (54.3%; 66.1%)	45.3% (39.6%; 51.9%)	33.1% (27.6%; 39.6%)	31.4% (25.8%; 38.1%)	26.2% (20.8%; 33.0%)	17.9% (12.4%; 25.7%)
X/NA	1,755	72.7% (70.4%; 75.0%)	63.5% (61.0%; 66.3%)	58.9% (56.0%; 61.9%)	55.5% (52.2%; 58.9%)	52.4% (48.6%; 56.5%)	42.4% (33.3%; 53.9%)

4.2.3. Kidney cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	19,032	89.5% (89.0%; 90.0%)	85.6% (85.0%; 86.2%)	82.7% (82.0%; 83.4%)	80.9% (80.1%; 81.7%)	79.0% (78.1%; 80.0%)	72.2% (70.0%; 74.5%)
Males							
All	12,523	89.4% (88.8%; 90.0%)	85.4% (84.6%; 86.2%)	82.4% (81.6%; 83.3%)	80.6% (79.6%; 81.6%)	78.6% (77.5%; 79.8%)	72.1% (69.4%; 75.0%)
I	7,453	97.9% (97.4%; 98.4%)	96.9% (96.2%; 97.6%)	95.4% (94.5%; 96.3%)	94.7% (93.6%; 95.8%)	93.7% (92.3%; 95.1%)	90.5% (86.7%; 94.4%)
II	1,051	96.2% (94.7%; 97.8%)	93.9% (91.8%; 96.1%)	91.1% (88.4%; 93.9%)	90.5% (87.4%; 93.7%)	87.4% (83.6%; 91.4%)	74.9% (67.5%; 83.0%)
III	1,819	89.8% (88.2%; 91.4%)	85.1% (83.1%; 87.2%)	81.7% (79.4%; 84.1%)	78.5% (75.9%; 81.2%)	75.9% (72.9%; 79.0%)	65.8% (59.3%; 72.9%)
IV	1,849	54.8% (52.4%; 57.2%)	40.2% (37.9%; 42.7%)	32.1% (29.8%; 34.6%)	26.7% (24.4%; 29.2%)	23.0% (20.7%; 25.5%)	9.0% (5.8%; 13.9%)
X/NA	458	74.1% (69.8%; 78.6%)	64.2% (59.3%; 69.5%)	59.1% (53.8%; 64.9%)	55.9% (50.2%; 62.2%)	51.4% (45.4%; 58.3%)	48.9% (37.1%; 64.3%)
Females							
All	6,509	89.7% (88.9%; 90.6%)	85.9% (84.9%; 86.9%)	83.2% (82.0%; 84.4%)	81.4% (80.1%; 82.8%)	79.8% (78.3%; 81.4%)	72.4% (68.6%; 76.3%)
I	3,924	98.8% (98.2%; 99.4%)	97.7% (96.8%; 98.6%)	96.6% (95.5%; 97.8%)	95.5% (94.0%; 96.9%)	95.3% (93.5%; 97.1%)	87.4% (82.1%; 93.2%)
II	540	91.9% (89.3%; 94.7%)	89.8% (86.6%; 93.1%)	86.2% (82.3%; 90.4%)	86.3% (82.0%; 90.9%)	83.8% (78.7%; 89.1%)	78.0% (66.6%; 91.3%)
III	943	89.4% (87.2%; 91.7%)	83.1% (80.3%; 86.0%)	80.9% (77.8%; 84.2%)	77.5% (73.9%; 81.3%)	73.9% (69.8%; 78.2%)	60.7% (52.9%; 69.7%)
IV	868	51.6% (48.3%; 55.2%)	37.1% (33.8%; 40.6%)	27.4% (24.3%; 30.9%)	24.0% (21.0%; 27.5%)	19.5% (16.5%; 23.0%)	13.8% (10.6%; 18.0%)
X/NA	272	77.3% (72.0%; 83.0%)	71.6% (65.7%; 78.1%)	68.9% (62.4%; 76.1%)	66.8% (59.7%; 74.7%)	65.1% (57.2%; 74.0%)	62.8% (46.9%; 84.1%)

5. CANCER SURVIVAL TRENDS



5.1. Kidney cancer survival trends: by tumour stage

5.1.1. Kidney cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	5,188	84.0% (82.9%; 85.1%)	75.9% (74.5%; 77.3%)	72.3% (70.7%; 74.0%)	3,089	85.6% (84.3%; 87.0%)	77.8% (76.1%; 79.6%)	72.6% (70.6%; 74.7%)
	I	2,174	96.3% (95.2%; 97.3%)	94.3% (92.7%; 96.0%)	93.5% (91.5%; 95.6%)	1,407	98.1% (97.0%; 99.2%)	95.9% (94.1%; 97.7%)	93.5% (91.0%; 96.1%)
	II	541	94.9% (92.6%; 97.3%)	89.2% (85.5%; 93.1%)	83.9% (79.1%; 88.9%)	288	96.3% (93.6%; 99.1%)	87.6% (82.8%; 92.7%)	82.2% (76.2%; 88.7%)
	III	812	88.3% (85.8%; 90.9%)	74.7% (71.0%; 78.5%)	66.9% (62.7%; 71.4%)	421	87.5% (84.1%; 91.0%)	75.4% (70.6%; 80.4%)	67.8% (62.2%; 73.7%)
	IV	834	44.7% (41.4%; 48.3%)	22.9% (20.0%; 26.2%)	17.5% (14.8%; 20.7%)	472	42.9% (38.6%; 47.7%)	23.0% (19.3%; 27.4%)	13.8% (10.6%; 17.9%)
	X/NA	846	79.9% (77.1%; 82.9%)	73.1% (69.6%; 76.7%)	69.3% (65.3%; 73.5%)	517	82.6% (79.1%; 86.2%)	74.4% (70.1%; 79.1%)	67.0% (62.0%; 72.4%)
2010-2014	All	5,055	86.8% (85.7%; 87.8%)	79.2% (77.8%; 80.6%)	74.8% (73.1%; 76.5%)	2,979	87.3% (86.0%; 88.6%)	79.5% (77.8%; 81.3%)	75.9% (73.9%; 78.1%)
	I	2,622	98.4% (97.6%; 99.2%)	97.6% (96.3%; 98.9%)	95.2% (93.3%; 97.2%)	1,603	98.5% (97.6%; 99.5%)	96.1% (94.5%; 97.8%)	94.4% (92.2%; 96.7%)
	II	484	95.3% (92.9%; 97.7%)	88.7% (84.8%; 92.7%)	84.4% (79.6%; 89.5%)	275	95.9% (93.1%; 98.8%)	93.2% (88.9%; 97.8%)	86.3% (80.4%; 92.6%)
	III	806	89.5% (87.1%; 92.0%)	75.1% (71.6%; 78.9%)	67.3% (63.2%; 71.7%)	413	90.3% (87.1%; 93.6%)	75.7% (70.9%; 80.8%)	69.3% (63.9%; 75.3%)
	IV	760	48.2% (44.6%; 52.0%)	24.5% (21.4%; 27.9%)	16.4% (13.8%; 19.6%)	423	42.9% (38.3%; 48.0%)	20.7% (16.9%; 25.3%)	15.7% (12.3%; 20.1%)
	X/NA	416	69.3% (64.7%; 74.2%)	60.7% (55.3%; 66.7%)	55.9% (49.6%; 63.1%)	274	76.2% (71.0%; 81.9%)	64.5% (58.0%; 71.7%)	59.5% (51.9%; 68.3%)
2015-2019	All	5,785	87.8% (86.8%; 88.8%)	80.7% (79.5%; 82.0%)	77.4% (75.8%; 79.0%)	3,129	89.2% (88.0%; 90.4%)	82.4% (80.7%; 84.1%)	78.9% (76.9%; 81.1%)
	I	3,265	97.8% (97.0%; 98.6%)	96.0% (94.7%; 97.3%)	94.6% (92.7%; 96.5%)	1,802	99.0% (98.1%; 99.9%)	96.4% (94.7%; 98.1%)	94.9% (92.6%; 97.4%)
	II	500	96.0% (93.8%; 98.4%)	89.8% (86.1%; 93.8%)	87.5% (82.8%; 92.5%)	267	93.7% (90.3%; 97.3%)	87.6% (82.3%; 93.3%)	84.2% (77.8%; 91.2%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	873	87.7% (85.2%; 90.2%)	78.2% (74.8%; 81.6%)	72.4% (68.4%; 76.5%)	455	87.4% (84.1%; 90.8%)	79.3% (74.9%; 83.9%)	72.5% (67.2%; 78.1%)
	IV	893	50.6% (47.3%; 54.1%)	28.6% (25.5%; 32.0%)	20.1% (17.3%; 23.3%)	426	51.6% (47.0%; 56.8%)	28.5% (24.2%; 33.5%)	20.3% (16.4%; 25.0%)
	X/NA	293	76.3% (71.1%; 81.9%)	62.3% (55.7%; 69.6%)	55.6% (48.3%; 64.2%)	190	77.5% (71.2%; 84.4%)	68.1% (60.5%; 76.8%)	65.7% (56.5%; 76.5%)
2020-2024	All	6,796	90.9% (90.1%; 91.7%)	83.9% (82.7%; 85.1%)	79.4% (77.6%; 81.2%)	3,400	90.2% (89.1%; 91.4%)	83.9% (82.3%; 85.6%)	80.6% (78.0%; 83.2%)
	I	4,221	98.1% (97.4%; 98.8%)	94.9% (93.7%; 96.2%)	92.5% (90.3%; 94.6%)	2,126	98.6% (97.7%; 99.4%)	96.9% (95.3%; 98.5%)	95.7% (92.7%; 98.7%)
	II	551	96.4% (94.2%; 98.6%)	92.1% (88.1%; 96.2%)	86.0% (79.5%; 93.1%)	273	90.1% (86.1%; 94.3%)	84.7% (79.0%; 90.7%)	82.3% (73.9%; 91.8%)
	III	946	91.8% (89.7%; 93.9%)	85.3% (82.1%; 88.5%)	80.1% (75.5%; 84.9%)	489	91.3% (88.4%; 94.3%)	82.8% (78.4%; 87.4%)	74.6% (67.4%; 82.7%)
	IV	956	58.6% (55.5%; 62.0%)	35.4% (32.0%; 39.1%)	26.1% (22.4%; 30.5%)	442	51.6% (47.0%; 56.6%)	26.0% (21.8%; 31.1%)	18.1% (13.6%; 24.3%)
	X/NA	165	70.0% (62.9%; 77.9%)	53.0% (44.5%; 63.2%)	41.9% (32.0%; 54.8%)	82	76.5% (67.4%; 86.7%)	67.6% (56.3%; 81.3%)	62.9% (49.8%; 79.4%)

6. CANCER MORTALITY



6.1. Kidney cancer mortality: by region

6.1.1. Kidney cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023

N [CR]																						ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages		
Males																							
Belgium	0	0	0	0	0	0	1	0	1	5	12	13	25	39	54	43	54	41	26	4	318	6.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[1.3]	[3.0]	[3.2]	[6.7]	[12.3]	[20.3]	[21.2]	[43.2]	[51.4]	[83.0]	[66.0]	[5.5]	(5.5; 6.8)	
Brussels	0	0	0	0	0	0	1	0	0	1	1	1	2	2	2	3	1	2	1	1	18	4.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[0.0]	[2.3]	[2.4]	[2.8]	[6.9]	[9.4]	[11.9]	[23.8]	[12.4]	[40.0]	[43.4]	[186.6]	[3.0]	(2.5; 7.0)	
Flanders	0	0	0	0	0	0	0	0	0	1	6	6	16	18	34	26	41	30	21	3	202	6.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[2.6]	[2.5]	[7.0]	[9.2]	[20.7]	[19.9]	[49.7]	[55.8]	[100.9]	[75.6]	[6.0]	(5.3; 7.0)	
Wallonia	0	0	0	0	0	0	0	0	1	3	5	6	7	19	18	14	12	9	4	0	98	6.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.5]	[4.0]	[4.8]	[6.0]	[18.8]	[21.1]	[23.2]	[34.9]	[43.0]	[48.6]	[0.0]	[5.4]	(4.9; 7.3)	
Females																							
Belgium	0	0	0	0	0	0	0	0	1	2	4	6	10	13	16	26	25	40	27	7	177	2.5	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.5]	[1.0]	[1.5]	[2.6]	[3.8]	[5.4]	[10.6]	[14.4]	[29.9]	[38.1]	[33.6]	[3.0]	(2.1; 2.8)	
Brussels	0	0	0	0	0	0	0	0	0	1	1	0	1	1	2	0	2	0	4	0	12	2.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[2.6]	[0.0]	[3.3]	[4.0]	[9.3]	[0.0]	[15.6]	[0.0]	[70.5]	[0.0]	[1.9]	(0.9; 3.5)	

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	0	0	1	1	3	2	6	7	7	16	17	25	16	2	103	2.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[1.3]	[0.8]	[2.6]	[3.5]	[4.0]	[10.6]	[15.5]	[29.3]	[36.4]	[16.3]	[3.0]	(1.9; 2.8)
Wallonia	0	0	0	0	0	0	0	0	0	0	0	4	3	5	7	10	6	15	7	5	62	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.2]	[2.4]	[4.5]	[7.0]	[12.9]	[11.6]	[38.8]	[33.0]	[77.1]	[3.3]	(2.1; 3.4)

7. CANCER MORTALITY TRENDS



7.1. Kidney cancer mortality trends: by region

7.1.1. Kidney cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	305	312	304	347	341	330	353	313	335	352	359	338	358	327	325	351	307	325	308	318		
	CR	6.0	6.1	5.9	6.7	6.5	6.3	6.6	5.8	6.2	6.5	6.6	6.1	6.5	5.9	5.8	6.2	5.4	5.7	5.4	5.5		
	ESR2013	8.6	8.6	7.9	8.6	8.5	8.2	8.5	7.3	7.8	8.2	8.0	7.6	7.6	7.1	6.8	7.2	6.1	6.5	6.1	6.1	-1.9 (-2.2; -1.5)	2004-2023
																						-1.0 (-1.7; -0.3)	2004-2015
																						-3.1 (-4.0; -2.1)	2016-2023
Brussels	N	27	28	19	14	31	16	24	24	20	21	29	19	28	20	15	24	17	16	21	18		
	CR	5.6	5.8	3.9	2.8	6.1	3.1	4.6	4.4	3.6	3.7	5.1	3.3	4.8	3.4	2.6	4.1	2.8	2.7	3.5	3.0		
	ESR2013	9.0	8.6	6.8	4.8	9.4	4.6	7.2	7.0	5.9	6.5	8.7	5.3	8.2	5.4	4.6	7.3	4.7	4.8	6.1	4.7	-2.0 (-3.8; -0.2)	2004-2023
Flanders	N	214	194	206	223	216	198	221	196	205	226	216	218	231	189	215	210	203	212	193	202		
	CR	7.2	6.5	6.9	7.4	7.1	6.5	7.2	6.3	6.5	7.2	6.8	6.8	7.2	5.9	6.6	6.4	6.2	6.4	5.8	6.0		
	ESR2013	10.2	8.6	8.8	9.0	8.8	7.9	8.5	7.3	7.6	8.3	7.7	8.0	7.7	6.6	7.1	6.8	6.4	6.7	6.0	6.2	-2.2 (-2.6; -1.8)	2004-2023
Wallonia	N	64	90	79	110	94	116	108	93	110	105	114	101	99	118	95	117	87	97	94	98		
	CR	3.9	5.5	4.8	6.6	5.6	6.9	6.4	5.4	6.4	6.1	6.5	5.8	5.6	6.7	5.4	6.6	4.9	5.4	5.2	5.4		
	ESR2013	5.4	8.6	6.0	8.8	7.5	9.9	8.9	7.6	8.8	8.3	8.3	7.5	7.1	8.6	6.6	8.2	5.7	6.6	6.3	6.1	-0.6 (-1.7; 0.6)	2004-2023
																						3.7 (0.6; 6.9)	2004-2012

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
																					-3.5 (-5.6; -1.5)	2013-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Kidney cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	245	218	211	237	222	217	231	193	207	259	235	176	234	195	192	203	205	187	192	177	-2.6 (-3.3; -1.9)	2004-2023
	CR	4.6	4.1	3.9	4.4	4.1	4.0	4.2	3.5	3.7	4.6	4.1	3.1	4.1	3.4	3.3	3.5	3.5	3.2	3.3	3.0		
	ESR2013	4.7	4.0	3.8	4.2	3.8	3.8	3.9	3.2	3.4	4.1	3.7	2.8	3.7	2.9	2.8	3.0	3.0	2.7	2.7	2.5		
Brussels	N	27	21	20	24	16	19	17	8	14	21	13	16	18	11	15	7	9	9	9	12	-5.3 (-7.3; -3.2)	2004-2023
	CR	5.2	4.0	3.8	4.5	3.0	3.4	3.0	1.4	2.4	3.5	2.2	2.7	3.0	1.8	2.5	1.1	1.5	1.4	1.4	1.9		
	ESR2013	5.0	4.2	3.8	4.9	2.9	3.3	3.4	1.7	2.8	3.4	2.7	3.2	3.2	2.3	2.3	1.1	1.3	1.7	1.7	2.2		
Flanders	N	143	130	127	129	136	124	145	129	131	177	151	102	142	117	116	132	130	119	121	103	-2.8 (-3.6; -1.9)	2004-2023
	CR	4.7	4.2	4.1	4.2	4.4	3.9	4.6	4.0	4.1	5.5	4.7	3.1	4.3	3.6	3.5	4.0	3.9	3.5	3.6	3.0		
	ESR2013	4.7	4.2	3.9	4.0	4.1	3.7	4.2	3.7	3.7	4.8	3.9	2.8	3.7	2.9	2.8	3.2	3.1	2.8	2.8	2.3		
Wallonia	N	75	67	64	84	70	74	69	56	62	61	71	58	74	67	61	64	66	59	62	62	-1.9 (-2.8; -1.1)	2004-2023
	CR	4.3	3.8	3.6	4.8	3.9	4.1	3.8	3.1	3.4	3.3	3.9	3.2	4.0	3.6	3.3	3.4	3.5	3.2	3.3	3.3		
	ESR2013	4.4	3.7	3.4	4.5	3.6	4.1	3.6	2.8	3.1	3.0	3.5	2.9	3.8	3.1	2.8	3.1	3.1	2.7	2.9	2.8		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026